Digital techniques could ‘turbocharge’ R&D after COVID-19, say UK chemistry leadersThe UK’s Royal Society of Chemistry has called for digital techniques to be more widely used as part Share XDigital techniques could ‘turbocharge’ R&D after COVID-19, say UK chemistry leadershttps://pharmaphorum.com/news/digital-techniques-could-turbocharge-rd-after-covid-19-say-uk-chemistry-leaders/
Chasing Merck, Eisai launches insomnia drug Dayvigo in JapanEisai has launched its insomnia drug Dayvigo in Japan, the second in a new class of medicines after Share XChasing Merck, Eisai launches insomnia drug Dayvigo in Japanhttps://pharmaphorum.com/news/chasing-merck-eisai-launches-insomnia-drug-dayvigo-in-japan/
UK trial begins testing second-wave COVID-19 drug from US biotech RidgebackThe AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential Share XUK trial begins testing second-wave COVID-19 drug from US biotech Ridgebackhttps://pharmaphorum.com/news/uk-trial-begins-testing-second-wave-covid-19-drug-from-us-biotech-ridgeback/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winSwitzerland’s Idorsia says it is on course to file a potential next-generation insomnia drug around the end of this year after a Share XIdorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial winhttps://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
European Commission approves Gilead’s remdesivir for COVID-19The European Commission has conditionally approved Gilead’s remdesivir for treatment of COVID-19, the first drug officially cleared for use against Share XEuropean Commission approves Gilead’s remdesivir for COVID-19https://pharmaphorum.com/news/european-commission-approves-gileads-remdesivir-for-covid-19/
NHS England will roll out online COVID-19 recovery portalPeople in the UK who are recovering from coronavirus infections will be able to get advice from an Share XNHS England will roll out online COVID-19 recovery portalhttps://pharmaphorum.com/news/nhs-england-will-roll-out-online-covid-19-recovery-portal/
GSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – reportGlaxoSmithKline and Sanofi are close to agreeing a £500m deal to supply the UK government with 60 million Share XGSK and Sanofi close in on £500m COVID-19 vaccine deal with UK – reporthttps://pharmaphorum.com/news/gsk-and-sanofi-close-in-on-500m-covid-19-vaccine-deal-with-uk-report/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
